-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Cyclerion Therapeutics (NASDAQ:CYCN) Stock Price Down 6.4%
Cyclerion Therapeutics (NASDAQ:CYCN) Stock Price Down 6.4%
Shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Get Rating) fell 6.4% during trading on Monday . The stock traded as low as $0.78 and last traded at $0.82. 161,207 shares changed hands during mid-day trading, a decline of 20% from the average session volume of 200,444 shares. The stock had previously closed at $0.88.
Cyclerion Therapeutics Stock Performance
The company has a market cap of $35.66 million, a PE ratio of -0.75 and a beta of 2.05. The company's 50-day simple moving average is $0.60 and its 200 day simple moving average is $0.71.
Get Cyclerion Therapeutics alerts:Cyclerion Therapeutics (NASDAQ:CYCN – Get Rating) last issued its quarterly earnings results on Thursday, November 3rd. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.11. Cyclerion Therapeutics had a negative net margin of 2,551.69% and a negative return on equity of 149.84%. Analysts forecast that Cyclerion Therapeutics, Inc. will post -1.16 EPS for the current year.
Hedge Funds Weigh In On Cyclerion Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Mackenzie Financial Corp purchased a new position in Cyclerion Therapeutics in the 1st quarter valued at approximately $28,000. Prudential Financial Inc. acquired a new stake in shares of Cyclerion Therapeutics in the 2nd quarter valued at $29,000. Jane Street Group LLC acquired a new stake in shares of Cyclerion Therapeutics in the 2nd quarter valued at $32,000. Prelude Capital Management LLC raised its holdings in shares of Cyclerion Therapeutics by 29.2% in the 1st quarter. Prelude Capital Management LLC now owns 100,255 shares of the company's stock valued at $111,000 after purchasing an additional 22,672 shares in the last quarter. Finally, Trustcore Financial Services LLC raised its holdings in shares of Cyclerion Therapeutics by 47.7% in the 1st quarter. Trustcore Financial Services LLC now owns 292,645 shares of the company's stock valued at $325,000 after purchasing an additional 94,539 shares in the last quarter. Hedge funds and other institutional investors own 48.34% of the company's stock.About Cyclerion Therapeutics
(Get Rating)
Cyclerion Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults.
Featured Articles
- Get a free copy of the StockNews.com research report on Cyclerion Therapeutics (CYCN)
- CrowdStrike Selloff: It's Time For Investors to Strike
- Pure Storage is a Steady Eddie Growing Storage Play
- Tesla Shares Are Sliding, Here's Why
- Insiders And Institutions Buy Fastenal, An Aristocrat To Be
- Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Get Rating) fell 6.4% during trading on Monday . The stock traded as low as $0.78 and last traded at $0.82. 161,207 shares changed hands during mid-day trading, a decline of 20% from the average session volume of 200,444 shares. The stock had previously closed at $0.88.
在週一的交易中，週期治療公司(納斯達克代碼：CYCN-GET評級)的股價下跌了6.4%。該股最低交易價格為0.78美元，最後報0.82美元。午盤交易中，161,207股股票易手，較200,444股的平均成交量下降了20%。該股此前收盤價為0.88美元。
Cyclerion Therapeutics Stock Performance
週期標準治療公司股票表現
The company has a market cap of $35.66 million, a PE ratio of -0.75 and a beta of 2.05. The company's 50-day simple moving average is $0.60 and its 200 day simple moving average is $0.71.
該公司市值為3,566萬美元，市盈率為-0.75，貝塔係數為2.05。該公司的50日簡單移動均線切入位在0.60美元，200日簡單移動均線切入位在0.71美元。
Cyclerion Therapeutics (NASDAQ:CYCN – Get Rating) last issued its quarterly earnings results on Thursday, November 3rd. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.11. Cyclerion Therapeutics had a negative net margin of 2,551.69% and a negative return on equity of 149.84%. Analysts forecast that Cyclerion Therapeutics, Inc. will post -1.16 EPS for the current year.
週期治療公司(納斯達克代碼：CYCN-GET Rating)上一次發佈季度收益報告是在11月3日星期四。該公司公佈了本季度每股收益(0.24美元)，比普遍預期的(0.35美元)高出0.11美元。週期治療公司的淨利潤率為負2551.69%，淨資產回報率為負149.84%。分析師預測，Cyclarie治療公司本年度的每股收益將達到1.16美元。
Hedge Funds Weigh In On Cyclerion Therapeutics
對衝基金對週期治療公司的看法
About Cyclerion Therapeutics
關於週期療法
(Get Rating)
(獲取評級)
Cyclerion Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults.
週期治療公司是一家臨牀階段的生物製藥公司，致力於治療嚴重中樞神經系統(CNS)疾病的藥物的發現、開發和商業化。它的主要候選產品是CY6463，這是一種中樞神經系統穿透性、可溶性鳥苷環化酶(SGC)刺激劑，正處於IIa期試驗，用於治療線粒體腦肌病、乳酸酸中毒和中風樣發作，以及有血管病變的阿爾茨海默病；以及成人精神分裂症的1期試驗。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Cyclerion Therapeutics (CYCN)
- CrowdStrike Selloff: It's Time For Investors to Strike
- Pure Storage is a Steady Eddie Growing Storage Play
- Tesla Shares Are Sliding, Here's Why
- Insiders And Institutions Buy Fastenal, An Aristocrat To Be
- Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
- 免費獲取StockNews.com關於週期療法(Cycn)的研究報告
- CrowdStrike拋售：投資者罷工的時候到了
- Pure Storage是穩步增長的存儲業務
- 特斯拉股價下滑，原因如下
- 內部人士和機構收購Fastenal，成為未來的貴族
- 大地塊是不是正在醖釀中的下一個牀上沐浴和超越災難？
Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《環素療法日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Cyclarion治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧